1 y in cells co-transfected with TRPC6 and AVP V1 receptor.

2 bition of transient receptor potential (TRP) V1 receptors.

3  vasopressin neurones co-express vasopressin V1 receptors.

4 ephrine, vasopressin, and F-180, a selective V1 receptor agonist, were measured at 24 hrs.

5 he nature and expression of both vasopressin V1 receptors and human VACM are apparently unaffected by

6 the cells co-transfected with TRPC6-EGFP and V1 receptor, and this response was inhibited by catalase

7 m (5 mg/kg) or an arginine vasopressin (AVP) V1 receptor antagonist (AVPX, 10 microgram/kg).

8 al olfactory contextual cues in males, and a V1 receptor antagonist stimulated such responses, at lea

9 cking agent, but not an arginine vasopressin V1 receptor antagonist, lowered blood pressure.

10 i.v. treatment with either phentolamine or a V1-receptor antagonist dissolved in saline.

11 ment with phentolamine or a vasopressinergic V1-receptor antagonist on the fetal cardiovascular respo

12                                            A V1-receptor antagonist produced a femoral vasodilatation

13                                            A V1-receptor antagonist shifted the effects of vasopressi

14 analogue that acts, via vascular vasopressin V1 receptors, as a systemic vasoconstrictor.

15      No differences in the sequences for the V1 receptors between classical and variant SCCL were fou